Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: Three further cases and current overview

Dermatology

Volumn 213, Issue 3, 2006, Pages 182-186

  Pirard, Delphine ^a,c   Arco, D ^b   Debrouckere, V ^a   Heenen, M ^a  

^a ERASME HOSPITAL   (Belgium)

^b CHU Andre Vesale   (Belgium)

^c NONE   (Belgium)

Author keywords

Anti TNF antibody; Psoriasiform eruption

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANAMNESIS; ANKYLOSING SPONDYLITIS; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; CROHN DISEASE; DERMATITIS; DERMATOMYCOSIS; DRUG CLASSIFICATION; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA MULTIFORME; ERYTHEMATOSQUAMOUS SKIN DISEASE; FAMILY HISTORY; FEMALE; FOLLICULITIS; GRANULOMA ANNULARE; HERPES SIMPLEX; HUMAN; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; LICHENOID ERUPTION; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; MEDICAL LITERATURE; MEDLINE; MOLLUSCUM CONTAGIOSUM; PAPULAR URTICARIA; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; RED MAN SYNDROME; RHEUMATOID ARTHRITIS; RISK FACTOR; SERUM SICKNESS; SKIN CANCER; SKIN DEFECT; SKIN DISEASE; SKIN INFECTION; SKIN LYMPHOMA; SKIN MANIFESTATION; STEROID THERAPY; TREATMENT DURATION; ULCERATIVE COLITIS; VESICULAR RASH;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750018558     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095033     Document Type: Article

References (20)

1. Thielen AM, Kuenzli S, Saurat JH: Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209-217.
2. Flendrie M, Vissers W, Creemers, de Jong E, van de Kerkhof P, van Kiel P: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-R676.
3. Grinblat B, Scheinberg M: Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum 2005;52:1333-1342.
4. Beuthien W, Mellighoff HU, von Kempis J: Skin reaction to adalimumab. Arthritis Rheum 2004;50:1690-1692.
5. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, De Keyser F, Veys EM: Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-834.
6. Verea M, Del Pozo J, Yebra-Pimentel M, Porta A, Fonseca E: Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004;38:54-57.
7. Thurber M, Feasel A, Stroehlein J, Hymes SR: Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004;3:439-440.
8. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ: Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol 2004;151:506-507.
9. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A: Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-2518.
10. Peramiquel L, Puig L, Dalmau J, Ricart E, Roé E, Alomar A: Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Derm 2005;30:713-714.
11. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E: Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumor necrosis factor alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153:1220-1247.
12. Krueger G, Callis K: Potential of tumor necrosis factor inhibitor in psoriasis and psoriatic arthritis. Arch Dermatol 2004;140:218-225.
13. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-2022.
14. Papp KA, Tyring S, Lahfa M, Pring J, Griffiths CEM, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L: A global phase III randomised trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction. Br J Dermatol 2005;152:1304-1312.
15. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG: Infliximab monotherapy provides rapid and sustained benefit for plaque type psoriasis. J Am Acad Dermatol 2003;48:829-835.
16. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-1374.
17. Aeberli D, Seitz M, Juni P, Villiger PM: Increase of peripheral CXR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors. Rheumatology 2005;44:172-175.
18. Srivastava MD, Alexander F, Tuthill RJ: Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 2005;61:329-336.
19. de Vlam K, Lories RJ: Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology 2006;45:321-324.
20. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R: A randomised trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-1632.